Tranexamic Acid (TXA) Dosing in Primary Total Knee ArthroplastyAre you Eligible?
Improving patient outcomes for Knee Arthroplasty
Total participants required
About this clinical trial
The number of people undergoing total knee arthroplasty (TKA) for osteoarthritis has been steadily increasing in Australia. There is a significant risk of blood loss during this procedure, resulting in prolonged hospital stay, pain and poor functional outcomes.
The purpose of this trial is to evaluate the effects of oral Tranexamic Acid (TXA) when administered pre-operatively.
The product is currently used to reduce bleeding during and after surgical procedures. This can lessen the chance of a blood transfusion and may decrease pain, swelling and recovery time following the operation.
Tranexamic Acid is already routinely used by surgeons for patients having joint replacements but there is currently no accurate information about how to dose individual patients with this medication to achieve the best results.
This study will assess whether different treatment durations and doses will lead to better patient outcomes.
Do you meet the following criteria?
People undergoing primary unilateral Total Knee Arthroplasty.
You can find out more about this clinical trial by visiting the ANZCTR website.
- Dr Sue Clark
A Prospective, Randomised Non-Blinded Pilot Study to Optimise Oral Tranexamic Acid Dosing in Primary Total Knee Arthroplasty
Register your interest
If you would like more information about this clinical trial, please complete the contact form below.